Waters Corporation (0LTI.L)
USD 370.56
(-0.36%)
USD 370.56
(-0.36%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.62 Billion USD | 41.0% |
| 2022 | 3.28 Billion USD | 6.03% |
| 2021 | 3.09 Billion USD | 8.98% |
| 2020 | 2.83 Billion USD | 11.06% |
| 2019 | 2.55 Billion USD | -31.4% |
| 2018 | 3.72 Billion USD | -30.19% |
| 2017 | 5.33 Billion USD | 14.53% |
| 2016 | 4.66 Billion USD | 9.41% |
| 2015 | 4.26 Billion USD | 9.86% |
| 2014 | 3.87 Billion USD | 8.49% |
| 2013 | 3.57 Billion USD | 12.85% |
| 2012 | 3.16 Billion USD | 16.38% |
| 2011 | 2.72 Billion USD | 16.95% |
| 2010 | 2.32 Billion USD | 21.47% |
| 2009 | 1.91 Billion USD | 18.07% |
| 2008 | 1.62 Billion USD | -13.72% |
| 2007 | 1.88 Billion USD | 16.31% |
| 2006 | 1.61 Billion USD | 13.18% |
| 2005 | 1.42 Billion USD | -2.16% |
| 2004 | 1.46 Billion USD | 29.14% |
| 2003 | 1.13 Billion USD | 11.86% |
| 2002 | 1.01 Billion USD | 13.99% |
| 2001 | 886.91 Million USD | 28.1% |
| 2000 | 692.34 Million USD | 18.47% |
| 1999 | 584.4 Million USD | 1.16% |
| 1998 | 577.7 Million USD | 4.64% |
| 1997 | 552.1 Million USD | 51.05% |
| 1996 | 365.5 Million USD | 21.91% |
| 1995 | 299.8 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 4.51 Billion USD | 1.41% |
| 2024 Q2 | 4.44 Billion USD | -1.33% |
| 2024 Q1 | 4.5 Billion USD | -2.55% |
| 2023 Q4 | 4.62 Billion USD | 2.88% |
| 2023 Q2 | 4.54 Billion USD | 37.54% |
| 2023 FY | 4.62 Billion USD | 41.0% |
| 2023 Q1 | 3.3 Billion USD | 0.77% |
| 2023 Q3 | 4.49 Billion USD | -1.12% |
| 2022 Q1 | 3.04 Billion USD | -1.73% |
| 2022 FY | 3.28 Billion USD | 6.03% |
| 2022 Q4 | 3.28 Billion USD | 6.89% |
| 2022 Q3 | 3.07 Billion USD | 0.97% |
| 2022 Q2 | 3.04 Billion USD | -0.02% |
| 2021 FY | 3.09 Billion USD | 8.98% |
| 2021 Q1 | 3.21 Billion USD | 13.09% |
| 2021 Q4 | 3.09 Billion USD | -0.67% |
| 2021 Q2 | 3.1 Billion USD | -3.36% |
| 2021 Q3 | 3.11 Billion USD | 0.4% |
| 2020 Q3 | 2.67 Billion USD | 1.17% |
| 2020 Q4 | 2.83 Billion USD | 6.0% |
| 2020 FY | 2.83 Billion USD | 11.06% |
| 2020 Q1 | 2.66 Billion USD | 4.28% |
| 2020 Q2 | 2.64 Billion USD | -0.68% |
| 2019 FY | 2.55 Billion USD | -31.4% |
| 2019 Q4 | 2.55 Billion USD | -0.16% |
| 2019 Q1 | 3.24 Billion USD | -12.82% |
| 2019 Q3 | 2.56 Billion USD | -9.27% |
| 2019 Q2 | 2.82 Billion USD | -13.13% |
| 2018 Q3 | 4.04 Billion USD | -2.76% |
| 2018 Q1 | 4.48 Billion USD | -15.92% |
| 2018 Q4 | 3.72 Billion USD | -7.81% |
| 2018 FY | 3.72 Billion USD | -30.19% |
| 2018 Q2 | 4.15 Billion USD | -7.39% |
| 2017 Q1 | 4.81 Billion USD | 3.19% |
| 2017 Q4 | 5.33 Billion USD | 3.42% |
| 2017 Q3 | 5.16 Billion USD | 3.33% |
| 2017 Q2 | 4.99 Billion USD | 3.87% |
| 2017 FY | 5.33 Billion USD | 14.53% |
| 2016 Q2 | 4.44 Billion USD | 1.82% |
| 2016 FY | 4.66 Billion USD | 9.41% |
| 2016 Q4 | 4.66 Billion USD | 1.86% |
| 2016 Q3 | 4.57 Billion USD | 2.89% |
| 2016 Q1 | 4.36 Billion USD | 2.52% |
| 2015 Q3 | 4.12 Billion USD | 2.29% |
| 2015 Q4 | 4.26 Billion USD | 3.39% |
| 2015 Q1 | 3.87 Billion USD | -0.16% |
| 2015 Q2 | 4.02 Billion USD | 4.03% |
| 2015 FY | 4.26 Billion USD | 9.86% |
| 2014 Q4 | 3.87 Billion USD | 3.39% |
| 2014 Q1 | 3.64 Billion USD | 2.08% |
| 2014 Q2 | 3.72 Billion USD | 2.13% |
| 2014 Q3 | 3.75 Billion USD | 0.65% |
| 2014 FY | 3.87 Billion USD | 8.49% |
| 2013 Q2 | 3.28 Billion USD | 2.44% |
| 2013 FY | 3.57 Billion USD | 12.85% |
| 2013 Q4 | 3.57 Billion USD | 4.38% |
| 2013 Q3 | 3.42 Billion USD | 4.25% |
| 2013 Q1 | 3.2 Billion USD | 1.24% |
| 2012 Q1 | 2.83 Billion USD | 4.27% |
| 2012 Q2 | 2.88 Billion USD | 1.55% |
| 2012 Q3 | 2.99 Billion USD | 3.94% |
| 2012 Q4 | 3.16 Billion USD | 5.71% |
| 2012 FY | 3.16 Billion USD | 16.38% |
| 2011 Q2 | 2.57 Billion USD | 5.1% |
| 2011 FY | 2.72 Billion USD | 16.95% |
| 2011 Q1 | 2.44 Billion USD | 5.13% |
| 2011 Q3 | 2.63 Billion USD | 2.63% |
| 2011 Q4 | 2.72 Billion USD | 3.17% |
| 2010 Q1 | 1.98 Billion USD | 3.84% |
| 2010 FY | 2.32 Billion USD | 21.47% |
| 2010 Q4 | 2.32 Billion USD | 5.53% |
| 2010 Q3 | 2.2 Billion USD | 8.31% |
| 2010 Q2 | 2.03 Billion USD | 2.78% |
| 2009 Q2 | 1.8 Billion USD | 7.65% |
| 2009 FY | 1.91 Billion USD | 18.07% |
| 2009 Q4 | 1.9 Billion USD | 1.19% |
| 2009 Q3 | 1.88 Billion USD | 4.6% |
| 2009 Q1 | 1.67 Billion USD | 3.18% |
| 2008 Q2 | 2.06 Billion USD | 4.56% |
| 2008 FY | 1.62 Billion USD | -13.72% |
| 2008 Q4 | 1.62 Billion USD | -22.86% |
| 2008 Q1 | 1.97 Billion USD | 4.96% |
| 2008 Q3 | 2.1 Billion USD | 1.91% |
| 2007 Q2 | 1.66 Billion USD | 2.36% |
| 2007 Q4 | 1.88 Billion USD | 5.54% |
| 2007 Q3 | 1.78 Billion USD | 6.93% |
| 2007 Q1 | 1.62 Billion USD | 0.68% |
| 2007 FY | 1.88 Billion USD | 16.31% |
| 2006 Q1 | 1.43 Billion USD | 0.77% |
| 2006 Q3 | 1.5 Billion USD | 2.2% |
| 2006 Q4 | 1.61 Billion USD | 7.68% |
| 2006 FY | 1.61 Billion USD | 13.18% |
| 2006 Q2 | 1.46 Billion USD | 2.06% |
| 2005 Q2 | 1.49 Billion USD | 0.68% |
| 2005 Q4 | 1.42 Billion USD | 5.47% |
| 2005 FY | 1.42 Billion USD | -2.16% |
| 2005 Q1 | 1.48 Billion USD | 1.5% |
| 2005 Q3 | 1.35 Billion USD | -9.22% |
| 2004 Q2 | 1.27 Billion USD | 2.12% |
| 2004 Q3 | 1.33 Billion USD | 4.93% |
| 2004 Q1 | 1.24 Billion USD | 10.05% |
| 2004 FY | 1.46 Billion USD | 29.14% |
| 2004 Q4 | 1.46 Billion USD | 9.52% |
| 2003 Q3 | 1.03 Billion USD | 2.25% |
| 2003 Q1 | 1.03 Billion USD | 2.81% |
| 2003 FY | 1.13 Billion USD | 11.86% |
| 2003 Q4 | 1.13 Billion USD | 9.56% |
| 2003 Q2 | 1 Billion USD | -2.88% |
| 2002 FY | 1.01 Billion USD | 13.99% |
| 2002 Q4 | 1.01 Billion USD | 2.16% |
| 2002 Q3 | 989.57 Million USD | -0.87% |
| 2002 Q2 | 998.22 Million USD | 7.24% |
| 2002 Q1 | 930.79 Million USD | 4.95% |
| 2001 Q4 | 886.91 Million USD | 7.5% |
| 2001 FY | 886.91 Million USD | 28.1% |
| 2001 Q2 | 776.12 Million USD | 8.09% |
| 2001 Q1 | 718.05 Million USD | 3.71% |
| 2001 Q3 | 825.04 Million USD | 6.3% |
| 2000 FY | 692.34 Million USD | 18.47% |
| 2000 Q1 | 592.37 Million USD | 1.36% |
| 2000 Q2 | 590.99 Million USD | -0.23% |
| 2000 Q3 | 649.41 Million USD | 9.89% |
| 2000 Q4 | 692.34 Million USD | 6.61% |
| 1999 Q4 | 584.4 Million USD | 1.48% |
| 1999 FY | 584.4 Million USD | 1.16% |
| 1999 Q1 | 555.9 Million USD | -3.77% |
| 1999 Q2 | 557.3 Million USD | 0.25% |
| 1999 Q3 | 575.9 Million USD | 3.34% |
| 1998 Q1 | 549.8 Million USD | -0.42% |
| 1998 FY | 577.7 Million USD | 4.64% |
| 1998 Q2 | 550.6 Million USD | 0.15% |
| 1998 Q3 | 554.3 Million USD | 0.67% |
| 1998 Q4 | 577.7 Million USD | 4.22% |
| 1997 Q2 | 365.8 Million USD | -0.19% |
| 1997 Q3 | 565.5 Million USD | 54.59% |
| 1997 Q4 | 552.1 Million USD | -2.37% |
| 1997 FY | 552.1 Million USD | 51.05% |
| 1997 Q1 | 366.5 Million USD | 0.27% |
| 1996 FY | 365.5 Million USD | 21.91% |
| 1996 Q1 | 295.8 Million USD | -1.33% |
| 1996 Q2 | 361.9 Million USD | 22.35% |
| 1996 Q4 | 365.5 Million USD | 0.47% |
| 1996 Q3 | 363.8 Million USD | 0.53% |
| 1995 Q1 | 324 Million USD | 0.0% |
| 1995 Q4 | 299.8 Million USD | -9.1% |
| 1995 Q2 | 338.8 Million USD | 4.57% |
| 1995 FY | 299.8 Million USD | 0.0% |
| 1995 Q3 | 329.8 Million USD | -2.66% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -826.941% |
| Dynavax Technologies Corporation | 997.09 Million USD | -364.033% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -228.384% |
| Perrigo Company plc | 10.8 Billion USD | 57.195% |
| Illumina, Inc. | 10.11 Billion USD | 54.239% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 95.313% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -492.92% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 94.29% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 82.659% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1979.429% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 86.013% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -6943.468% |
| Biogen Inc. | 26.84 Billion USD | 82.764% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -2698.726% |
| Evolus, Inc. | 188.99 Million USD | -2348.097% |
| Adicet Bio, Inc. | 207.29 Million USD | -2132.014% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -3576.658% |
| bluebird bio, Inc. | 619.16 Million USD | -647.278% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -2148.272% |
| FibroGen, Inc. | 423.52 Million USD | -992.453% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 57.011% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -16265.272% |
| Homology Medicines, Inc. | 47.05 Million USD | -9732.446% |
| Geron Corporation | 394.07 Million USD | -1074.102% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -20.809% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -494.803% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -285.989% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -1155.625% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -255.645% |
| Zoetis Inc. | 14.28 Billion USD | 67.613% |
| Abeona Therapeutics Inc. | 64 Million USD | -7129.234% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -37.886% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 32.372% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 79.644% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -8169.771% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -54.741% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -2695.615% |
| Verastem, Inc. | 149.71 Million USD | -2990.379% |
| Nektar Therapeutics | 398.03 Million USD | -1062.43% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -686.564% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -2243.838% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -41.729% |
| OPKO Health, Inc. | 2.01 Billion USD | -129.997% |
| Exelixis, Inc. | 2.94 Billion USD | -57.25% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -42.303% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -644.445% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2896.939% |
| uniQure N.V. | 831.68 Million USD | -456.32% |
| Imunon, Inc. | 21.91 Million USD | -21009.77% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -340.968% |
| Insmed Incorporated | 1.32 Billion USD | -247.926% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -166.944% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -393.732% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1303.834% |
| Incyte Corporation | 6.78 Billion USD | 31.779% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -152.158% |